Abstract: Objective  To evaluate the clinical efficacy and safety of apatinib combined with radiotherapy in patients with bone metastasis. Methods  Thirty-one patients admitted to Radiation Oncology of the First Affiliated Hospital of Anhui Medical University with bone metastasis were recruited from April 2016 to February 2017. All patients were received apatinib 500 mg/d orally combined with radiotherapy (30~40 Gy/10~20 F) until disease progression or intolerable toxicity occurred. Clinical efficacy and safety were observed. Results  The total response rate was 93.55% (29/31), 25.81% (8/31) had complete response, 58.06% (18/31) had moderate response, 9.68% (3/31) had mild response,  and 6.45% (2/31) had no response; The time to exert its effect after the treatment was 6 days, and its median maintenance time was 7 months. The lesions complete response was 3.23% (1/31), partial response was 51.61% (16/31), became stable in 13 patients (41.94%), and deteriorated in 1 patient (3.23%), and the total control rate was 96.78%. The patients Karnofsky score increased obviously after the treatment (83.71±5.77 vs. 78.87±7.49), and the difference was statistically significant (t=4.23, P=0.006). The median local progressionfree survival and median overall survival  were 6 months and 7 months, respectively. The main adverse reactions were hypertension, hand-foot syndrome， proteinuria and bone marrow depression. The rates of hypertension, hand-foot syndrome, proteinuria and bone marrow depression were 35.48% (11/31), 25.81% (8/31), 16.13% (5/31), and 16.13% (5/31), respectively. Conclusion  Radiotherapy combined with apatinib is effective and tolerable for bone metastasis patients.

Key words: Neoplasm metastasis, Radiotherapy, Bone tissue, Apatinib